Novartis AG ADR (NVS)vsSol Gel Technologies Ltd (SLGL)
NVS
Novartis AG ADR
$137.16
+1.36%
HEALTHCARE · Cap: $260.70B
SLGL
Sol Gel Technologies Ltd
$65.18
-1.15%
HEALTHCARE · Cap: $227.61M
Smart Verdict
WallStSmart Research — data-driven comparison
Novartis AG ADR generates 3158284% more annual revenue ($56.69B vs $1.79M). NVS leads profitability with a 22.5% profit margin vs 0.0%. NVS earns a higher WallStSmart Score of 51/100 (C-).
NVS
Buy51
out of 100
Grade: C-
SLGL
Avoid26
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-47.0%
Fair Value
$93.29
Current Price
$137.16
$43.87 premium
Intrinsic value data unavailable for SLGL.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 31 in profit
Strong operational efficiency at 34.6%
Keeps 23 of every $100 in revenue as profit
Generating 5.6B in free cash flow
Earnings expanding 487.6% YoY
Conservative balance sheet, low leverage
Areas to Watch
0.8% revenue growth
Grey zone — moderate risk
Elevated debt levels
Expensive relative to growth rate
Smaller company, higher risk/reward
0.0% margin — thin
Weak financial health signals
ROE of -2.0% — below average capital efficiency
Comparative Analysis Report
WallStSmart ResearchBull Case : NVS
The strongest argument for NVS centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 22.5% and operating margin at 34.6%.
Bull Case : SLGL
The strongest argument for SLGL centers on EPS Growth, Debt/Equity.
Bear Case : NVS
The primary concerns for NVS are Revenue Growth, Altman Z-Score, Debt/Equity.
Bear Case : SLGL
The primary concerns for SLGL are Market Cap, Profit Margin, Piotroski F-Score.
Key Dynamics to Monitor
SLGL carries more volatility with a beta of 1.13 — expect wider price swings.
NVS is growing revenue faster at 0.8% — sustainability is the question.
Monitor DRUG MANUFACTURERS - GENERAL industry trends, competitive dynamics, and regulatory changes.
Bottom Line
NVS scores higher overall (51/100 vs 26/100), backed by strong 22.5% margins. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Novartis AG ADR
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Novartis AG researches, develops, manufactures and markets medical devices worldwide. The company is headquartered in Basel, Switzerland.
Visit Website →Sol Gel Technologies Ltd
HEALTHCARE · BIOTECHNOLOGY · USA
Sol-Gel Technologies Ltd., a specialty clinical-stage pharmaceutical company, is focused on developing and commercializing topical dermatological pharmaceuticals based on its Israel-patented microencapsulation delivery system. The company is headquartered in Ness Ziona, Israel.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?